| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 1684 | 2020 |
| IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma ILM Reijers, D Rao, JM Versluis, AM Menzies, P Dimitriadis, MW Wouters, ... Journal of Experimental Medicine 220 (5), e20221952, 2023 | 21 | 2023 |
| Metabolic profiles of regulatory T cells in the tumour microenvironment D Rao, F Verburg, K Renner, DS Peeper, R Lacroix, CU Blank Cancer Immunology, Immunotherapy, 1-11, 2021 | 18 | 2021 |
| Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature … ILM Reijers, P Dimitriadis, EA Rozeman, JM Versluis, A Broeks, ... Journal of Clinical Oncology 38 (15_suppl), TPS10087-TPS10087, 2020 | 10 | 2020 |
| Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells EP Hoefsmit, PT van Royen, D Rao, JA Stunnenberg, P Dimitriadis, ... Cancer Immunology Research 11 (4), 450-465, 2023 | 4 | 2023 |
| MeVa2. 1. dOVA and MeVa2. 2. dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance D Rao, R Lacroix, A Rooker, T Gomes, JA Stunnenberg, M Valenti, ... Melanoma Research 33 (1), 12-26, 2023 | 4 | 2023 |
| Acidity‐mediated induction of FoxP3+ regulatory T cells D Rao, JA Stunnenberg, R Lacroix, P Dimitriadis, J Kaplon, F Verburg, ... European Journal of Immunology 53 (6), 2250258, 2023 | 3 | 2023 |
| IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 … EA Rozeman, JM Versluis, K Sikorska, EP Hoefsmit, P Dimitriadis, D Rao, ... Journal for Immunotherapy of Cancer 11 (7), 2023 | 3 | 2023 |
| Nafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in a hamster model L Cornelissen, E Hoefsmit, D Rao, J Lijnsvelt, L van Keulen, M van Es, ... bioRxiv, 2020.11. 09.372375, 2020 | 3 | 2020 |
| P01. 15 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to … ILM Reijers, EA Rozeman, P Dimitriadis, O Krijgsman, LJW Bosch, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 2), 2020 | 1 | 2020 |
| Impro ing immunotherap for melanoma: models, biomarkers and regulator T cells D Rao J Immunother 11 (7), e006821, 2023 | | 2023 |
| Dendritic cell-intrinsic PTPN22 negatively regulates anti-tumor immunity S Acero-Bedoya, EF Higgs, TF Gajewski Cancer Research 82 (12_Supplement), 2100-2100, 2022 | | 2022 |
| Nafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in a hamster model (preprint) L Cornelissen, E Hoefsmit, D Rao, J Lijnsvelt, L ven Keulen, M van Es, ... | | 2020 |
| Lack of in vivo effect of LMK235 on regulatory T cells and melanoma growth control D Rao, T Gomes, JA Stunnenberg, DS Peeper, CU Blank Improving Immunotherapy for Melanoma: Models, Biomarkers and Regulatory T …, 0 | | |
